New imaging method reveals causes of cerebral oedema
Neurobiology: Publication in the Journal for Neuroscience Cerebral oedema is a dangerous complication in many brain-related conditions such as strokes. Researchers at the Institute of […]
Month: January 2022
FDA approves Roche’s Vabysmo, the first bispecific antibody for the eye, to treat two leading causes of vision loss
Vabysmo (faricimab-svoa) targets and inhibits two disease pathways that drive neovascular or “wet” age-related macular degeneration (nAMD) and diabetic macular edema (DME) Vabysmo is the […]
Pfizer and BioNTech Publish Data from Two Laboratory Studies on COVID-19 Vaccine-induced Antibodies Ability to Neutralize SARS-CoV-2 Omicron Variant
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced the publication of new results from two laboratory studies demonstrating that three doses of […]
U.S. EPA and World Health Organization Partner to Protect Public Health
Agreement recognizes the increased environmental and public health risks from the warming global climate and prioritizes environmental justice This week, the U.S. Environmental Protection Agency […]
Suvoda Exceeds 2021 Targets; Poised for Continued Growth Supporting Complex Clinical Trials in 2022
Surpasses 900 trials across 65 countries, expands leadership team and product offerings, and posts another year of 30% growth, all while maintaining an exceptional performance […]
The Zika Virus´s Immune Escape Strategy
– Important Insights for the Development of Antiviral Therapies A research team led by the Paul-Ehrlich-Institut examined the interaction between the Zika virus and the […]
WHO Virtual Press Conference on COVID-19 and other global health issues, 18 January
WHO Director-General’s opening remarks at the media briefing on COVID-19 — 18 January 2022 The volcanic eruption near Tonga and subsequent tsunami requires an urgent […]
COVAX delivers its 1 billionth COVID-19 vaccine dose – with video
On 15 January 2021, a shipment of 1.1 million COVID-19 vaccines to Rwanda included the billionth dose supplied via COVAX. Together with our partners, COVAX […]
WHO Interim statement on COVID-19 vaccines
Interim Statement on COVID-19 vaccines in the context of the circulation of the Omicron SARS-CoV-2 Variant from the WHO Technical Advisory Group on COVID-19 Vaccine […]
BioNTech and InstaDeep Developed and Successfully Tested Early Warning System to Detect Potential High-Risk SARS-CoV-2 Variants
Early Warning System combines Spike protein structural modeling with artificial intelligence (AI) to detect and monitor high-risk SARS-CoV-2 variants, identifying >90% of WHO-designated variants on […]
Immune Biosolutions reports that its lead immunotherapy product IBIO123 neutralizes 100% of the SARS-CoV-2 variants of concern (VOCs), including Omicron
Immune Biosolutions Inc., a clinical-stage company, is pleased to announce that its leading biological drug candidate maintains a potent activity in neutralization assays. Recent results […]
BioNTech and Crescendo Biologics Announce Global Collaboration to Develop Multi-specific Precision Immunotherapies
Collaboration leverages BioNTech’s proprietary multimodal immunotherapy expertise with Crescendo’s proprietary Humabody® VH platform to develop precision immunotherapies, including mRNA-based antibodies and engineered cell therapies against […]
For the first time in medical history, an autonomous drone helps save the life of a cardiac arrest patient
For the first time in medical history, a drone has played a crucial part in saving a life during a sudden cardiac arrest. The world […]
Adare Pharma Solutions Announces Appointment of Tom Sellig as Chief Executive Officer
Sellig Will Drive Enhanced Customer Service and Go-To-Market Strategy Adare Pharma Solutions (“Adare”), a global, technology-driven contract development and manufacturing organization (CDMO), today announced the […]
Definitive Agreement to Acquire Exelead will Strengthen Merck’s CDMO Offering for mRNA
Merck has signed a definitive agreement to acquire Exelead, a biopharmaceutical contract development and manufacturing organization (CDMO), for approximately USD 780 million in cash. Targeted […]